La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Alvotech Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Alvotech sono diminuiti a un tasso medio annuo di -37.2%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 11.8%. I ricavi sono cresciuti crescere a un tasso medio annuo di 374.6%.

Informazioni chiave

-37.2%

Tasso di crescita degli utili

92.8%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	21.5%
Tasso di crescita dei ricavi	374.6%
Rendimento del capitale proprio	n/a
Margine netto	-200.3%
Prossimo aggiornamento sui guadagni	21 Nov 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Alvotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

ICSE:ALVO Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	309	-618	62	209
31 Mar 24	114	-494	67	191
31 Dec 23	93	-552	74	192
30 Sep 23	64	-596	120	179
30 Jun 23	65	-416	82	175
31 Mar 23	100	-713	101	182
31 Dec 22	85	-514	76	181
30 Sep 22	96	61	51	171
30 Jun 22	78	-12	34	187
31 Mar 22	39	-42	66	190
31 Dec 21	40	-102	68	191
31 Dec 20	69	-170	59	146
31 Dec 19	83	-210	49	96

Guadagni di qualità: ALVO al momento non è redditizia.

Margine di profitto in crescita: ALVO al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ALVO non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 37.2% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ALVO nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ALVO non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -0.08% ).

Rendimento del capitale proprio

ROE elevato: Le passività di ALVO superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Alvotech Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Full year 2023 earnings released: US$2.43 loss per share (vs US$2.60 loss in FY 2022)

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Recent updates

Alvotech Initiates Confirmatory Patient Study for AVT16

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$2.43 loss per share (vs US$2.60 loss in FY 2022)

Alvotech Announces Executive Changes

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Alvotech to Report Q1, 2023 Results on May 18, 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$2.60 loss per share (vs US$0.92 loss in FY 2021)

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Less than half of directors are independent

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

Alvotech to Report Nine Months, 2022 Results on Nov 15, 2022

Alvotech Announces Executive Changes

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Initiates Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech to Report Q2, 2022 Results on Aug 31, 2022

Alvotech Initiates Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Expands its Board of Directors as Part of Transition from Private to Publicly Traded Company

Alvotech Initiates Patient Study for AVT06

No independent directors

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili